SecBot SecBot

ALDX

Aldeyra Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001341235 Biotech & Drug Discovery
$0.6593 +0.01 (+1.43%)
Oct 26 4:00 PM ET · prev $0.6500
Market cap
$38.9M
Nano cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
$5.00
+658% · range $2.00–13.00
Next earnings
Nov 2
in 7 days · EPS est. −$0.09
1 year
−87.4%
from $5.23 · Oct 27
30 days
−43.2%
from $1.16
52-week range
$0.6450–5.62
−88% from high · low Oct 22
Avg volume 20D
2.08M
Oct 6 spike 8.23M
Short interest
3.47M
≈5.8% of shares · −3.7%
Days to cover
3.0
at average volume
Insider net
+$523.5K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 3 reports · 90 days
Balance 1 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 2, 2026
Strongest BULLISH Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $523.5K at an average $1.61. No open-market sales. Price is 59% below their cost.

  • InstitutionsMIXED

    Q2 2026: 13 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.077 → −$0.092 over 90 days. 0 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest −3.7% to 3.47M shares. 3.0 days to cover, ≈5.8% of shares.

  • TrendDOWNTREND

    46% below its 50-day average. New closing low $0.6450 on Oct 22.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
D. E. Shaw & Co., Inc.ADD1,940,338$4.1M
MARSHALL WACE, LLPDOUBLED1,506,974$3.2M
JANE STREET GROUP, LLCADD1,375,115$2.9M
BlackRock, Inc.TRIM1,257,243$2.7M
Qube Research & Technologies LtdDOUBLED1,128,803$2.4M
GOLDMAN SACHS GROUP INCADD725,444$1.5M
GEODE CAPITAL MANAGEMENT, LLCTRIM596,029$1.3M
CITADEL ADVISORS LLCADD379,144$807.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy4Buy5Hold2Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +658%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 30, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral
Sep 29, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$523.5K
bought · 3 insiders
$0
sold · 0 insiders
−59.1%
vs their $1.61 cost
DateInsiderTypeValue
Jun 9, 2026
DEPTULA-HICKS DARLENE M
Director
AWARD84,557 sh
Jun 9, 2026
Bronstein Ben
Director
AWARD70,000 sh
Jun 9, 2026
Walker Neal
Director
AWARD70,000 sh
Jun 9, 2026
Clark William D
Director
AWARD70,000 sh
Jun 9, 2026
Miller-Rich Nancy
Director
AWARD70,000 sh
Jun 9, 2026
DOUGLAS RICHARD
Director
AWARD70,000 sh
Jun 9, 2026
Phillips Gary M.
Director
AWARD70,000 sh
Jun 9, 2026
Clark William D
Director
AWARD2,323 sh

Earnings setup

Estimates
Nov 2
reports in 7 days
−$0.09
EPS estimate, this quarter
−21%
estimate change, 90 days
0↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.09-$0.11–-$0.08+0.0%$0.00
Next Q-$0.10-$0.13–-$0.08+0.0%$0.00
Current FY-$0.34-$0.39–-$0.31+0.0%$0.00
Next FY-$0.28-$0.40–-$0.16+0.0%$6.7M

Short side

FINRA· Sep 30, 2026
3,470,527
shares short
-3.7%
vs prior settlement
3.0
days to cover
≈5.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 SEC
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of…
8-K — Impact 7/10
Aug 16, 2026 SEC
A bearish institutional cluster formed in ALDX during 2026-Q2, with 9 sellers reducing holdings by $6.9M versus 4…
INST-CLUSTER — Impact 6/10
Aug 5, 2026 Earnings calendar
ALDX Q2 2026 Earnings Scheduled — 2026-08-05
Jul 30, 2026 SEC
ALDX executed a 3-year commercial lease for ~4,067 sq ft of office space in Concord, MA to serve as its new corporate…
8-K — Impact 2/10
Jun 30, 2026 Inst.
D. E. Shaw & — ADD
1,940,338 shares ($4.1M)
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — DOUBLED
1,506,974 shares ($3.2M)
Jun 9, 2026 Insider
DEPTULA-HICKS DARLENE M was granted 84,557 shares
Director
Jun 9, 2026 Insider
Bronstein Ben was granted 70,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
ALDX Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Aug 5, 2026
Earnings date
ALDX Q2 2026 Earnings Scheduled — 2026-08-05
Jul 15, 2026
Short interest
Short Interest: ALDX down 37% to 3.6M shares
Settlement 2026-07-15 | Days to cover: 1.99 | ≈5.96% of shares outstanding (est.)
Jun 3, 2026
Clinical Trial
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
Phase 2 · COMPLETED
May 14, 2026
Clinical Trial
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
Phase 3 · COMPLETED
Apr 23, 2026
Clinical Trial
A Study in Subjects With Retinitis Pigmentosa
Phase 2 · COMPLETED

SecBot reports

6 filings · 2 bullish · 1 bearish · 3 neutral
All ALDX filing & press-release reports (6)